Organised by Open Society Foundations in collaboration with EPHA and EUPHA
This session will be a highly interactive discussion between moderators, panelists and the audience. It aims to articulate a common diagnosis of the inefficiencies and challenges of the current pharmaceutical innovation system, and outline possible remedies and alternatives based on successes and good practices in areas such as neglected diseases.
Despite a narrative of unprecedented medical progress, there is increasing evidence that the current market-driven model of pharmaceutical innovation is deficient. Even with growing research and development spending – including from the public – critical medical needs remain unmet, while the large majority of new medicines developed have little or no added therapeutic value to what already exists. Learning from successful experience with non-market driven innovation, we must fundamentally re-think how medical innovation is organised and financed to reinstate effective and “healthy” innovation that benefits patients, and is affordable and sustainable for society.
The regulator’s perspective: Is faster access to new health technologies really what we need? Where is this road leading to?
Beate Wieseler, Head of the Drug Assesment Department, Institute for Quality and Efficiency in Healthcare (IQWiG)
The negotiator’s perspective: Is affordability feasible?
Maurice Galla, Directorate for Pharmaceuticals and Medical Technology, Ministry of Health, Welfare and Sport, The Netherlands
Towards a public interest oriented medical innovation system in Europe
Yannis Natsis, Policy Coordinator, Universal Access and Affordable Medicines, European Public Health Alliance (EPHA) | Young Forum Gastein Network
Martin McKee, Professor for Public Health, London School of Hygiene and Tropical Medicine
Developing therapeutic advances for neglected diseases outside the market: Matching unmet needs with scientific opportunities in a cost-effective way
Bernard Pécoul, Executive Director, Drugs for Neglected Diseases Initiative (DNDi)
Addressing AMR: a growing consensus on new innovation models
John-Arne Rottingen, Professor of Health Policy, Department of Health Management and Health Economics, University of Oslo
Future scenarios for drug development & pricing
Raf Mertens, Director, Belgian Healthcare Knowledge Centre
Els Torreele, Director, Access to Medicines and Innovation, Open Society Foundations (OSF)